In boys but not girls, reduced sleep duration at age 8 and 10 years predicted the development of behavioral disorder symptoms 2 years later.
The researchers analyzed data from 1649 combat-exposed United States military veterans who were evaluated at a Veterans Affairs facility between 2009 and 2012 after deployment to the wars in Iraq and/or Afghanistan.
The Food and Drug Administration (FDA) has approved Dayvigo (lemborexant; Eisai) for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance in adult patients.
Sleep fragmentation, defined by low sleep efficiency, is associated with increased odds of migraine a day later, but there is no temporal association for short sleep duration and low sleep quality with migraine.
A stepped care approach seems beneficial for insomnia treatment among cancer survivors.
The researchers found that adults with ASD showed significant impairments in both objective (10 of 17 total outcomes) and subjective (6 of 11 total outcomes) measures of sleep compared with controls.
In this sample of preschoolers, sleep disorders were commonly reported and associated with specific diagnostic categories.
Investigators sought to determine the mental health needs of evacuees of devastating wildfires in Canada and to distribute evidence-based tools to promote resilience.
Anna S. Urrila, MD and colleagues sought to explore whether sleep symptoms in adolescents with MDD were associated with long-term outcomes.
Sleep abnormalities, the most common symptom of PTSD, are observed in approximately 70% of patients, indicating that sleep problems may play an important role in the development and maintenance of the disorder.